Waldenström macroglobulinemia: What a hematologist needs to know.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Blood reviews

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.blre.2015.03.001PMID 25882617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ibrutinib in previously treated Waldenström's macroglobulinemia.

  2015cited by this paper
• Guidelines on the diagnosis and management of Waldenström macroglobulinaemia

  2014cited by this paper
• Long‐term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

  2014cited by this paper
• C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.

  2014cited by this paper
• Outcomes of young patients with Waldenstrom macroglobulinemia (WM).

  2014cited by this paper
• The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.

  2014cited by this paper
• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

  2014cited by this paper
• Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database.

  2014cited by this paper
• Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.

  2014influential reference
• Choice of therapy for patients with Waldenstrom macroglobulinemia.

  2013cited by this paper
• Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

  2013cited by this paper
• Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study.

  2013cited by this paper
• MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

  2013cited by this paper
• Cryoglobulinemic disease.

  2013cited by this paper
• A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

  2013cited by this paper
• Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstrom’s Macroglobulinemia

  2013cited by this paper
• Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population‐based study of 1,555 patients diagnosed in Sweden from 1980 to 2005

  2013cited by this paper
• Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.

  2013cited by this paper
• A new era for Waldenstrom macroglobulinemia: MYD88 L265P.

  2013cited by this paper
• Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia

  2013cited by this paper
• Changing Epidemiology and Improved Survival In Patients With Waldenstrom Macroglobulinemia: Review Of Surveillance, Epidemiology, and End Results (SEER) Data

  2013influential reference
• Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia

  2013cited by this paper
• Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

  2013cited by this paper
• MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

  2013cited by this paper
• Phase II Trial In Advanced Waldenstrom Macroglobulinemia (WM) Patients With Bortezomib: Interest Of Addition Of Dexamethasone To Bortezomib On Behalf Of The French CLL/WM Intergroup (NCT 00777738)

  2013cited by this paper
• Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

  2013cited by this paper
• L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma

  2013cited by this paper
• Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.

  2013influential reference
• Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

  2013cited by this paper
• Blockade of Myd88 signaling induces antitumor effects by skewing the immunosuppressive function of myeloid‐derived suppressor cells

  2013cited by this paper
• Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

  2013cited by this paper
• A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

  2013cited by this paper
• Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue

  2013cited by this paper
• Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia

  2012cited by this paper
• MYD88 L265P mutation in Waldenstrom macroglobulinemia.

  2012cited by this paper
• Familial Aggregation of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia with Solid Tumors and Myeloid Malignancies

  2012cited by this paper
• MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

  2012cited by this paper
• Heterogeneous spectrum of neuropathies in Waldenström's macroglobulinemia: a diagnostic strategy to optimize their management

  2012cited by this paper
• Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

  2012cited by this paper
• Temporal and geographic variations of Waldenstrom macroglobulinemia incidence

  2012cited by this paper
• Hematopoietic cell transplantation for Waldenström macroglobulinemia

  2012cited by this paper
• Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

  2012cited by this paper
• Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

  2012cited by this paper
• Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique

  2012cited by this paper
• Progression in smoldering Waldenstrom macroglobulinemia: long-term results.

  2012influential reference
• MYD88 L265P somatic mutation in IgM MGUS.

  2012cited by this paper
• A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenström Macroglobulinemia

  2012cited by this paper
• Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells

  2011cited by this paper
• Novel M-component based biomarkers in Waldenström's macroglobulinemia.

  2011cited by this paper
• High-throughput genomic analysis in Waldenström's macroglobulinemia.

  2011cited by this paper
• Jak/Stat pathway in Waldenström's macroglobulinemia.

  2011cited by this paper
• Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia.

  2011cited by this paper
• Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.

  2011cited by this paper
• Attainment of complete/very good partial response following rituximab‐based therapy is an important determinant to progression‐free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

  2011influential reference
• Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab‐containing regimen

  2011cited by this paper
• Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity.

  2011cited by this paper
• Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia

  2011cited by this paper
• Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.

  2011cited by this paper
• Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy.

  2011cited by this paper
• The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia

  2011cited by this paper
• MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts

  2011cited by this paper
• Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström's macroglobulinemia.

  2011cited by this paper
• Incidence of Peripheral Neuropathy in Waldenström Macroglobulinemia Patients At Diagnosis

  2011cited by this paper
• Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.

  2010influential reference
• High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

  2010cited by this paper
• microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.

  2010cited by this paper
• No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years

  2010cited by this paper
• Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

  2010cited by this paper
• Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.

  2010cited by this paper
• A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

  2010cited by this paper
• Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

  2010cited by this paper
• Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia

  2010cited by this paper
• Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation.

  2010cited by this paper
• The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia

  2010cited by this paper
• Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

  2010cited by this paper
• Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

  2010cited by this paper
• Hierarchical Organization of Osteoblasts and Their Impact on Hematopoietic Stem Cell Maintenance and Function.

  2010cited by this paper
• Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

  2010influential reference
• Fcγ receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma.

  2010cited by this paper
• Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

  2010cited by this paper
• Pathophysiology of Waldenström’s macroglobulinemia

  2010cited by this paper
• IgA and IgG hypogammaglobulinemia in Waldenström’s macroglobulinemia

  2010cited by this paper
• The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)

  2009cited by this paper
• Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy.

  2009cited by this paper
• Two Cases of Hyperglobulinaemia with Affection of the Central Nervous System on a Toxi‐Infectious Basis.1

  2009cited by this paper
• Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

  2009cited by this paper
• Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome?

  2009cited by this paper
• Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

  2009cited by this paper
• Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease.

  2009cited by this paper
• Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.

  2009cited by this paper
• Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

  2009influential reference
• Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).

  2009cited by this paper
• Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trial

  2009cited by this paper
• Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

  2009cited by this paper
• International prognostic scoring system for Waldenstrom macroglobulinemia.

  2009cited by this paper
• Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia

  2009cited by this paper
• Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study.

  2009cited by this paper
• Assessment of bone marrow response in Waldenström's macroglobulinemia.

  2009cited by this paper

• Case Report: Pulmonary and gastrointestinal involvement in a rare case of Waldenström’s Macroglobulinemia in French Guiana

  2025cites this paper
• Morbus Waldenström - die „Hydra unter den Lymphomen“

  2025cites this paper
• Modern possibilities for diagnosing and tumor clone monitoring, determined by multicolor flow cytometry, in Waldenstrom’s macroglobulinemia

  2025cites this paper
• A Rare Case of Combined Direct Retinal Involvement and Suspected Bing-Neel Syndrome in a Patient With Waldenstrom’s Macroglobulinemia

  2024cites this paper
• Bilateral reversible optic neuropathy as the first sign of Waldenström macroglobulinema

  2024cites this paper
• Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network

  2024cites this paper
• Current approach to Waldenström macroglobulinemia.

  2023cites this paper
• Baseline 18F-FDG PET/CT May Portend the Prognosis of Patients With Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma After First-Line Treatment

  2022cites this paper
• Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies.

  2022cites this paper
• [Waldenström disease: News and perspectives in 2022].

  2022cites this paper
• A synergistic multitargeted of BET and HDAC: an intra-molecular mechanism of communication in treatment of Waldenström macroglobulinemia

  2021cites this paper
• Chylothorax as an Initial Manifestation of Waldenström macroglobulinemia

  2020cites this paper
• LUBAC accelerates B-cell lymphomagenesis by conferring B cells resistance to genotoxic stress.

  2020cites this paper
• Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.

  2020influential citation
• Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management

  2020cites this paper
• Rare lymphomas in routine practice—Treatment and outcome in Waldenström's macroglobulinaemia in the prospective German Tumour Registry Lymphatic Neoplasms

  2020cites this paper
• THE ROLE OF THE TUMOR MICROENVIRONMENT IN WALDENSTRÖM MACROGLOBULINEMIA

  2019influential citation
• Targeting IL-6 reduces IgM levels and tumor growth in Waldenström macroglobulinemia

  2019cites this paper
• 68Ga-Pentixafor PET/CT for Imaging of Chemokine Receptor 4 Expression in Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT

  2019cites this paper
• Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia

  2019cites this paper
• Retrospective evaluation of chromosome 1 anomalies in hematologic malignancies: A single center study

  2019cites this paper
• Cutaneous Infiltration due to Waldenström Macroglobulinemia.

  2018cites this paper
• Hämatologische Diagnose in der Hornhautsprechstunde

  2018cites this paper
• Waldenstrom’s Macroglobulinemia: An Update

  2018cites this paper
• Thrombotic microangiopathy with intraglomerular IgM pseudothrombi in Waldenström macroglobulinemia and IgM monoclonal gammopathy

  2018cites this paper
• [Hematological diagnosis in the corneal consultation].

  2018cites this paper
• Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

  2018cites this paper
• Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains

  2017cites this paper
• Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment‐naïve patients with Waldenstrom macroglobulinemia

  2017cites this paper
• Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016

  2017cites this paper
• Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

  2017cites this paper
• 64-Year-Old Woman With Weakness and Fall.

  2017cites this paper
• conditional expression of Myd 88 ( p . L 252 P ) leads to the development of diffuse large B cell lymphoma in mice

  2017cites this paper
• CXCR4-Specific Nanobodies as Potential Therapeutics for WHIM syndrome

  2017cites this paper
• Advances in the understanding of IgM monoclonal gammopathy of undetermined significance

  2017cites this paper
• Waldenström′s macroglobulinemia: Two malignant clones in a monoclonal disease? Molecular background and clinical reflection

  2017cites this paper
• Waldenström macroglobulinemia: biology, genetics, and therapy

  2016cites this paper
• Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection

  2016cites this paper
• Severe Thrombocytopenia in a Splenectomized Patient with Waldenstrom Macroglobulinemia

  2016cites this paper
• LYMPHOID NEOPLASIA B-cell – speci fi c conditional expression of Myd88 p.L252P leads to the development of diffuse large B-cell lymphoma in mice by Sequencing Project

  2016cites this paper
• Neither the patient nor the physician could see anything: Atypical Bing–Neel syndrome

  2016cites this paper
• Neurologic Manifestations of Blood Dyscrasias.

  2016cites this paper
• “I Have Macroglobulinemia, and Now What?”—Case Report

  2016cites this paper
• B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.

  2016cites this paper
• Ibrutinib for the treatment of Waldenström macroglobulinemia

  2015cites this paper
• Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma

  2015cites this paper
• Cancer Management and Research Dovepress

  year unknowncites this paper